Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Buprenorphine | 7 | 2022 | 121 | 2.320 |
Why?
|
| Opioid-Related Disorders | 11 | 2021 | 333 | 2.110 |
Why?
|
| Substance Withdrawal Syndrome | 5 | 2021 | 177 | 1.400 |
Why?
|
| Opiate Substitution Treatment | 6 | 2016 | 73 | 1.380 |
Why?
|
| Amphetamine-Related Disorders | 3 | 2021 | 129 | 1.290 |
Why?
|
| Methamphetamine | 3 | 2021 | 236 | 1.190 |
Why?
|
| Cocaine-Related Disorders | 6 | 2017 | 258 | 1.160 |
Why?
|
| Dextroamphetamine | 1 | 2021 | 42 | 0.920 |
Why?
|
| Sertraline | 3 | 2017 | 47 | 0.810 |
Why?
|
| Methadone | 5 | 2013 | 167 | 0.800 |
Why?
|
| Patient Compliance | 3 | 2016 | 272 | 0.760 |
Why?
|
| Central Nervous System Stimulants | 1 | 2021 | 250 | 0.740 |
Why?
|
| Analgesics, Opioid | 4 | 2019 | 446 | 0.670 |
Why?
|
| Cyclohexanecarboxylic Acids | 2 | 2014 | 23 | 0.670 |
Why?
|
| Amines | 2 | 2014 | 47 | 0.670 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2014 | 79 | 0.640 |
Why?
|
| Depression | 3 | 2014 | 596 | 0.540 |
Why?
|
| Child Abuse | 1 | 2016 | 168 | 0.530 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2010 | 402 | 0.520 |
Why?
|
| Methadyl Acetate | 2 | 2010 | 11 | 0.510 |
Why?
|
| Narcotics | 2 | 2010 | 111 | 0.480 |
Why?
|
| Adult | 18 | 2021 | 14221 | 0.410 |
Why?
|
| Reward | 1 | 2010 | 120 | 0.400 |
Why?
|
| Double-Blind Method | 5 | 2021 | 751 | 0.400 |
Why?
|
| Behavior Therapy | 1 | 2010 | 202 | 0.350 |
Why?
|
| Young Adult | 6 | 2021 | 4239 | 0.350 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 3 | 2014 | 49 | 0.350 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2006 | 65 | 0.320 |
Why?
|
| Pilot Projects | 4 | 2021 | 797 | 0.320 |
Why?
|
| Female | 19 | 2021 | 28639 | 0.310 |
Why?
|
| Male | 18 | 2021 | 27947 | 0.310 |
Why?
|
| Anxiety | 2 | 2022 | 267 | 0.300 |
Why?
|
| Narcotic Antagonists | 4 | 2021 | 123 | 0.290 |
Why?
|
| Retrospective Studies | 6 | 2022 | 5933 | 0.290 |
Why?
|
| Humans | 22 | 2022 | 52189 | 0.280 |
Why?
|
| Serotonin Uptake Inhibitors | 3 | 2017 | 121 | 0.270 |
Why?
|
| Veterans | 2 | 2010 | 633 | 0.270 |
Why?
|
| Health Status | 1 | 2006 | 383 | 0.270 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 704 | 0.260 |
Why?
|
| Disulfiram | 2 | 2013 | 12 | 0.240 |
Why?
|
| Databases, Factual | 2 | 2019 | 689 | 0.230 |
Why?
|
| Outpatients | 1 | 2022 | 119 | 0.220 |
Why?
|
| Naloxone | 2 | 2013 | 61 | 0.220 |
Why?
|
| Quality of Life | 1 | 2006 | 805 | 0.210 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 243 | 0.200 |
Why?
|
| Self Report | 3 | 2016 | 191 | 0.200 |
Why?
|
| Time Factors | 4 | 2011 | 3413 | 0.200 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2021 | 442 | 0.200 |
Why?
|
| Prescription Drug Misuse | 1 | 2019 | 29 | 0.190 |
Why?
|
| Middle Aged | 11 | 2021 | 13540 | 0.190 |
Why?
|
| Patient Dropouts | 2 | 2016 | 62 | 0.190 |
Why?
|
| Drug Monitoring | 1 | 2019 | 90 | 0.190 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 1535 | 0.170 |
Why?
|
| Ambulatory Care | 2 | 2016 | 230 | 0.160 |
Why?
|
| Life Change Events | 1 | 2016 | 47 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2013 | 1559 | 0.160 |
Why?
|
| Age Factors | 2 | 2010 | 1261 | 0.160 |
Why?
|
| Treatment Outcome | 4 | 2017 | 5572 | 0.150 |
Why?
|
| Prevalence | 2 | 2016 | 992 | 0.150 |
Why?
|
| GABA Agonists | 1 | 2014 | 18 | 0.140 |
Why?
|
| Prospective Studies | 3 | 2021 | 2402 | 0.140 |
Why?
|
| Alcohol Deterrents | 1 | 2013 | 9 | 0.130 |
Why?
|
| Diltiazem | 1 | 2013 | 9 | 0.130 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2013 | 58 | 0.130 |
Why?
|
| Risk-Taking | 1 | 2014 | 138 | 0.130 |
Why?
|
| Verapamil | 1 | 2013 | 21 | 0.130 |
Why?
|
| Logistic Models | 1 | 2016 | 1020 | 0.130 |
Why?
|
| Suicidal Ideation | 1 | 2014 | 93 | 0.120 |
Why?
|
| Calcium Channel Blockers | 1 | 2013 | 69 | 0.120 |
Why?
|
| Suicide | 1 | 2014 | 86 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 429 | 0.120 |
Why?
|
| Medication Adherence | 1 | 2014 | 148 | 0.120 |
Why?
|
| Motivation | 1 | 2014 | 286 | 0.120 |
Why?
|
| Recurrence | 1 | 2014 | 694 | 0.120 |
Why?
|
| Internet | 1 | 2014 | 295 | 0.110 |
Why?
|
| Token Economy | 1 | 2010 | 33 | 0.110 |
Why?
|
| Electrocardiography | 1 | 2013 | 303 | 0.110 |
Why?
|
| Income | 1 | 2010 | 95 | 0.110 |
Why?
|
| Severity of Illness Index | 3 | 2013 | 1106 | 0.110 |
Why?
|
| Affect | 1 | 2011 | 107 | 0.100 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2011 | 95 | 0.100 |
Why?
|
| Substance Abuse Detection | 1 | 2010 | 96 | 0.100 |
Why?
|
| Hospitals, Veterans | 1 | 2010 | 156 | 0.100 |
Why?
|
| Choice Behavior | 1 | 2010 | 96 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2011 | 359 | 0.100 |
Why?
|
| Sleep | 1 | 2011 | 191 | 0.100 |
Why?
|
| Adolescent | 3 | 2016 | 6805 | 0.090 |
Why?
|
| Benzhydryl Compounds | 1 | 2009 | 82 | 0.090 |
Why?
|
| Heart Rate | 1 | 2011 | 365 | 0.090 |
Why?
|
| Blood Pressure | 1 | 2011 | 540 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2010 | 797 | 0.090 |
Why?
|
| Cognition | 1 | 2011 | 347 | 0.090 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 627 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 636 | 0.090 |
Why?
|
| Arkansas | 1 | 2014 | 2178 | 0.080 |
Why?
|
| Personality Inventory | 1 | 2006 | 51 | 0.080 |
Why?
|
| Child | 2 | 2016 | 6788 | 0.080 |
Why?
|
| Combat Disorders | 1 | 2006 | 48 | 0.080 |
Why?
|
| Psychometrics | 1 | 2006 | 243 | 0.070 |
Why?
|
| African Americans | 1 | 2010 | 719 | 0.070 |
Why?
|
| Comorbidity | 1 | 2006 | 695 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 2006 | 397 | 0.060 |
Why?
|
| Cocaine | 2 | 2017 | 176 | 0.060 |
Why?
|
| Secondary Prevention | 2 | 2013 | 88 | 0.060 |
Why?
|
| Limit of Detection | 1 | 2021 | 18 | 0.060 |
Why?
|
| Linear Models | 1 | 2021 | 318 | 0.050 |
Why?
|
| Postpartum Period | 1 | 2021 | 99 | 0.050 |
Why?
|
| United States | 1 | 2010 | 5046 | 0.050 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2017 | 7 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1315 | 0.040 |
Why?
|
| Chronic Pain | 1 | 2019 | 136 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1055 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 508 | 0.030 |
Why?
|
| Directly Observed Therapy | 1 | 2013 | 8 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 1408 | 0.030 |
Why?
|
| Pregnancy | 1 | 2021 | 2402 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2013 | 45 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2013 | 72 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2013 | 52 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2014 | 167 | 0.030 |
Why?
|
| Calcium Channels, L-Type | 1 | 2013 | 66 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2013 | 220 | 0.030 |
Why?
|
| Placebos | 1 | 2011 | 98 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 533 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 263 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2008 | 200 | 0.020 |
Why?
|
| Aged | 1 | 2014 | 10361 | 0.010 |
Why?
|